Major Human Trial Launches to Test Three FDA-Approved Drugs for Healthspan and New Regulatory Endpoint

The holy grail of longevity medicine has long been stymied by a fundamental bureaucratic paradox: the United States Food and Drug Administration does not recognize aging as a disease. Consequently, there has been no clear regulatory pathway to approve a drug that simply keeps people healthier for longer, forcing researchers to target specific illnesses instead. That paradigm is now facing its most significant challenge to date. The Advanced Research Projects Agency for Health (ARPA-H) has awarded $38 million to the University of Texas Health Science Center at San Antonio to launch VITAL-H, a landmark Phase 3 clinical trial designed to rewrite the rules of aging research.[1][2]

Unlike previous longevity studies that relied heavily on animal models, yeast cells, or abstract biological clocks that measure cellular age, VITAL-H is testing three existing, FDA-approved drugs directly in healthy human subjects. The primary objective is not to measure absolute lifespan—which would require a trial lasting decades—but to establish a regulatory-grade endpoint for 'healthspan'. Healthspan is defined as the period of life spent free from chronic disease, cognitive decline, and physical disability, representing the kind of aging that patients and clinicians actually care about.[3][7]

The trial is preparing to enroll between 700 and 1,000 adults aged 60 to 65 across South Texas, specifically targeting individuals who are currently in relatively good health. Participants will be randomized to receive either a placebo or one of three generic or widely available medications: rapamycin, dapagliflozin, or semaglutide. By repurposing drugs that have already cleared stringent FDA safety hurdles for other conditions, researchers hope to dramatically accelerate the timeline from clinical testing to widespread preventative use, bypassing the decade-long safety evaluations required for novel compounds.[2][3]

The first major intervention centers on rapamycin, a drug originally approved as an immunosuppressant to prevent organ rejection in transplant recipients, which now holds the most robust preclinical pedigree in the entire field of geroscience. It works by inhibiting the mTOR pathway, a central cellular regulator of growth and metabolism. In the National Institute on Aging's rigorous Interventions Testing Program, rapamycin consistently extended the lifespan of mice by 9% to 26% across multiple strains. In the VITAL-H trial, researchers are testing whether low, intermittent oral doses can trigger cellular cleanup—a regenerative process known as autophagy—in humans without dangerously suppressing the immune system.[3][7]

The second intervention tests the claim that dapagliflozin provides systemic metabolic protection. Dapagliflozin belongs to a class of drugs known as SGLT2 inhibitors, initially developed to lower blood sugar in type 2 diabetes by prompting the kidneys to excrete glucose. However, massive clinical trials have recently revealed that SGLT2 inhibitors offer profound cardio-renal protection, significantly reducing the risk of heart failure and kidney disease even in non-diabetic patients. The VITAL-H trial will evaluate whether this systemic metabolic shielding translates to a broader deceleration of biological aging.[2][4]

The third pillar of the trial examines semaglutide's capacity to reduce systemic inflammation and metabolic stress across the body. Semaglutide, a GLP-1 receptor agonist famous globally for its profound weight-loss efficacy, has a scientific story that extends far beyond simple appetite suppression. Emerging clinical evidence indicates that GLP-1 agonists significantly improve endothelial function, protect against major cardiovascular events, and reduce markers of systemic inflammation. Researchers hypothesize that semaglutide's ability to induce steady-state metabolic resilience could make it a potent, multi-system anti-aging intervention for the general population, rather than just a treatment for obesity.[3][4]

The most revolutionary aspect of the VITAL-H trial is not the specific drugs being tested, but the clinical endpoint they are being measured against. Because the FDA strictly requires therapies to treat specific, diagnosable conditions, the trial is utilizing a comprehensive framework originally developed by the World Health Organization known as 'Intrinsic Capacity'. Intrinsic capacity is a composite measure of an individual's physical and mental functionality, encompassing locomotor ability, cognition, psychological health, sensory function, and overall vitality. Rather than waiting decades to see if participants live longer, researchers will measure tangible, near-term changes in how well participants walk, think, and maintain their physical strength over the course of the study.[3][4][5]

The stated goal of the research team, led by Dr. Elena Volpi, is to convince the FDA to recognize intrinsic capacity as a meaningful, regulatory-grade endpoint for clinical trials. If the FDA accepts this composite metric as a valid measure of efficacy, it would create a fast-track template for the entire longevity industry. This regulatory shift would allow future therapies to be approved based on their proven ability to preserve functional capacity and delay the onset of frailty, rather than forcing companies to prove they can cure a specific end-stage disease like Alzheimer's or heart failure.[2][4][7]

To capture this complex functional data, the trial is employing a decentralized, high-tech monitoring model that moves research out of the clinic and into the real world. Participants will be equipped with advanced wearable technology, including smart rings and fitness straps, to provide a continuous stream of digital biomarkers. This continuous data collection marks a stark departure from traditional clinical trials, which rely on occasional, snapshot clinic visits that can miss day-to-day fluctuations in health. By tracking sleep architecture, resting heart rate, heart rate variability, and daily mobility in real-time, researchers can detect subtle shifts in physiological resilience long before clinical symptoms appear.[3][7]

Despite the widespread optimism surrounding the trial, significant clinical uncertainties remain regarding the universal application of these drugs. Clinical pharmacists and skeptical researchers note that while medications like semaglutide and dapagliflozin clearly improve longevity and reduce mortality in patients with specific chronic conditions—such as diabetes, obesity, or heart failure—their effects on healthy individuals are less predictable. Moving outside of these specific, diseased populations makes it difficult to determine whether the longevity benefits will translate to a general, healthy population, or if the drugs might introduce unnecessary side effects without providing a proportional healthspan benefit.[4]

There is also the critical question of durability and long-term physiological dependence. The VITAL-H protocol includes a mandatory six-month washout period at the end of the active intervention phase. Researchers will closely monitor participants after they completely stop taking the medications to determine if the improvements in healthspan and intrinsic capacity persist independently. The field needs to know whether these drugs permanently alter the trajectory of biological aging, or if the biological clock rapidly accelerates to catch up once the chemical intervention is removed from the patient's system.[7]

Furthermore, the regulatory hurdle facing the research team remains formidable, regardless of the trial's clinical success. The FDA's Biomarker Qualification Program has historically set an exceptionally high bar for surrogate endpoints, typically restricting them to highly specific disease contexts, such as drug-induced kidney injury or cardiovascular risk in diabetic patients. Convincing the agency to accept a broad, composite functional score as a primary efficacy claim for a preventative therapy will require overwhelming, unequivocal data that proves intrinsic capacity directly correlates with long-term health outcomes.[6][7]

If successful, the ARPA-H PROSPR initiative could fundamentally restructure the economic model of the modern pharmaceutical industry. Currently, the industry is heavily incentivized to develop expensive, late-stage treatments for complex, chronic diseases that require lifelong management. By validating a clear regulatory pathway for healthspan, VITAL-H could shift financial incentives toward cheap, generic, preventative interventions that keep populations out of the hospital in the first place, potentially saving the healthcare system billions of dollars annually. This shift would transform aging from an inevitable decline into a treatable, manageable condition, opening up a massive new market for preventative therapeutics.[1][7]

The final, peer-reviewed results of the VITAL-H trial are not expected until the early 2030s, meaning the field must exercise patience as the data matures. Until then, the global longevity industry, regulatory bodies, and healthcare economists will be watching the trial's progress closely. For the first time in medical history, the debate over human life extension has moved out of the speculative realm of biohacking and into the rigorous, heavily regulated arena of a federally funded Phase 3 clinical trial, marking a new era in the science of aging.[3][7]